EPISODE · Jun 2, 2025 · 14 MIN
ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
from BiotechTV - News · host BiotechTV
CEO David Chang\ describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on Allogene's 1L consolidation trial in LBCL, and his thoughts on cell therapy for autoimmune diseases.
Embed this episode
NOW PLAYING
ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
0:00
14:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 14 minutes long.
When was this BiotechTV - News episode published?
This episode was published on June 2, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!